Treatment of Eosinophilic Annular Erythema: ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
Treatment of Eosinophilic Annular Erythema: Retrospective multicenter study and literature review.
Auteur(s) :
Chastagner, M. [Auteur]
Hôpital Edouard Herriot [CHU - HCL]
Université Claude Bernard Lyon 1 [UCBL]
Shourik, J. [Auteur]
CHU Tenon [AP-HP]
Jachiet, M. [Auteur]
Service de Dermatologie [AP-HP Hôpital Saint-Louis]
Hopital Saint-Louis [AP-HP] [AP-HP]
Battistella, M. [Auteur]
Immunologie humaine, physiopathologie & immunothérapie [HIPI (UMR_S_976 / U976)]
Hopital Saint-Louis [AP-HP] [AP-HP]
Lefevre, Guillaume [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Gibier, Jean-Baptiste [Auteur]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Aubert, H. [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Service de dermatologie [Nantes]
Musquer, M. [Auteur]
Descamps, V. [Auteur]
AP-HP - Hôpital Bichat - Claude Bernard [Paris]
Deschamps, L. [Auteur]
Chosidow, O. [Auteur]
Dynamic Microbiology - EA 7380 [DYNAMIC]
Université Paris-Est Créteil Val-de-Marne - Paris 12 [UPEC UP12]
Hôpital Henri Mondor
Ortonne, N. [Auteur]
Groh, M. [Auteur]
Hôpital Foch [Suresnes]
Bernier, M. [Auteur]
Jullien, D. [Auteur]
Chasset, F. [Auteur]
Staumont, delphine [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Bouaziz, J. D. [Auteur]
Kanikatis, J. [Auteur]
Villani, A. P. [Auteur]
Hôpital Edouard Herriot [CHU - HCL]
Université Claude Bernard Lyon 1 [UCBL]
Shourik, J. [Auteur]
CHU Tenon [AP-HP]
Jachiet, M. [Auteur]
Service de Dermatologie [AP-HP Hôpital Saint-Louis]
Hopital Saint-Louis [AP-HP] [AP-HP]
Battistella, M. [Auteur]
Immunologie humaine, physiopathologie & immunothérapie [HIPI (UMR_S_976 / U976)]
Hopital Saint-Louis [AP-HP] [AP-HP]
Lefevre, Guillaume [Auteur]

Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Gibier, Jean-Baptiste [Auteur]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Aubert, H. [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Service de dermatologie [Nantes]
Musquer, M. [Auteur]
Descamps, V. [Auteur]
AP-HP - Hôpital Bichat - Claude Bernard [Paris]
Deschamps, L. [Auteur]
Chosidow, O. [Auteur]
Dynamic Microbiology - EA 7380 [DYNAMIC]
Université Paris-Est Créteil Val-de-Marne - Paris 12 [UPEC UP12]
Hôpital Henri Mondor
Ortonne, N. [Auteur]
Groh, M. [Auteur]
Hôpital Foch [Suresnes]
Bernier, M. [Auteur]
Jullien, D. [Auteur]
Chasset, F. [Auteur]
Staumont, delphine [Auteur]

Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Bouaziz, J. D. [Auteur]
Kanikatis, J. [Auteur]
Villani, A. P. [Auteur]
Titre de la revue :
Annales de Dermatologie et de Vénéréologie
Nom court de la revue :
Ann Dermatol Venereol
Date de publication :
2021-11-06
ISSN :
0151-9638
Mot(s)-clé(s) en anglais :
Eosinophilic annular erythema
Eosinophil
Wells syndrome
Eosinophilic cellulitis
Treatment
Eosinophil
Wells syndrome
Eosinophilic cellulitis
Treatment
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Background
Eosinophilic annular erythema (EAE) is a rare eosinophil-related skin disease which typically manifests with annular erythematous plaques and severe pruritus. Besides the diagnosis, the treatment of EAE is ...
Lire la suite >Background Eosinophilic annular erythema (EAE) is a rare eosinophil-related skin disease which typically manifests with annular erythematous plaques and severe pruritus. Besides the diagnosis, the treatment of EAE is challenging since relevant published data are sparse. Methods The aim of this study was to assess the underlying diseases, treatments and outcomes of patients with EAE. To this end, we conducted a retrospective multicenter study and a systematic review of the MEDLINE database. Results We included 18 patients with EAE followed in 8 centers. The MEDLINE database search yielded 37 relevant publications reporting 55 cases of EAE with 106 treatment sequences. The most common and efficient treatments included topical or systemic corticosteroids, hydroxychloroquine and dapsone. In refractory patients, a combination of systemic corticosteroids with hydroxychloroquine was associated with 88% of complete clinical response. Discussion To improve the management of EAE patients, we discuss the following treatment strategy: in topical steroid-resistant patients, hydroxychloroquine can be given as first-line systemic treatment. Dapsone, hydroxychloroquine or systemic corticosteroids are second-line options to consider. Last, monoclonal antibodies or JAK inhibitors targeting type 2 inflammation could represent promising last-resort options in refractory patients.Lire moins >
Lire la suite >Background Eosinophilic annular erythema (EAE) is a rare eosinophil-related skin disease which typically manifests with annular erythematous plaques and severe pruritus. Besides the diagnosis, the treatment of EAE is challenging since relevant published data are sparse. Methods The aim of this study was to assess the underlying diseases, treatments and outcomes of patients with EAE. To this end, we conducted a retrospective multicenter study and a systematic review of the MEDLINE database. Results We included 18 patients with EAE followed in 8 centers. The MEDLINE database search yielded 37 relevant publications reporting 55 cases of EAE with 106 treatment sequences. The most common and efficient treatments included topical or systemic corticosteroids, hydroxychloroquine and dapsone. In refractory patients, a combination of systemic corticosteroids with hydroxychloroquine was associated with 88% of complete clinical response. Discussion To improve the management of EAE patients, we discuss the following treatment strategy: in topical steroid-resistant patients, hydroxychloroquine can be given as first-line systemic treatment. Dapsone, hydroxychloroquine or systemic corticosteroids are second-line options to consider. Last, monoclonal antibodies or JAK inhibitors targeting type 2 inflammation could represent promising last-resort options in refractory patients.Lire moins >
Langue :
Anglais
Comité de lecture :
Oui
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Université de Lille
Inserm
CHU Lille
Inserm
CHU Lille
Collections :
Date de dépôt :
2024-01-12T05:45:19Z
2024-02-29T09:01:18Z
2024-02-29T09:01:18Z